StockNews.AI
ONC
StockNews.AI
78 days

BeOne Medicines presenteert nieuwe SEQUOIA-studieresultaten die BRUKINSA’s gedifferentieerd profiel versterken met of zonder Venetoclax bij frontline chronische lymfatische leukemie (CLL) tijdens ASCO 2025

1. BRUKINSA shows high response rates in CLL patients with del(17p) mutation. 2. Five-year follow-up indicates improved overall and progression-free survival. 3. Data originates from pivotal Phase 3 SEQUOIA study's Arms C and D. 4. Results may enhance ONC's position in oncology market. 5. Overall safety profile of BRUKINSA remains favorable for treatment.

2m saved
Insight
Article

FAQ

Why Bullish?

The promising results from the SEQUOIA study could improve investor confidence, similar to historical impacts following favorable clinical trial results. Past instances have shown stock prices can rise significantly after positive trial announcements.

How important is it?

The study results could lead to increased adoption of BRUKINSA, enhancing ONC's market value and relevance in advanced CLL care and impacting investor outlook substantially.

Why Long Term?

The sustained survival advantages evident in the study highlight potential for long-term market growth, positioning ONC positively in future oncology treatments.

Related Companies

BEIGCELGABBV

SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), een wereldwijd oncologiebedrijf, zal vandaag nieuwe gegevens presenteren van de cohorten Arm C en D van de pivotale, globale fase 3 SEQUOIA-studie van BRUKINSA® (zanubrutinib).

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.

Related News